A randomized comparative trial evaluating the safety and efficacy of liposomal amphotericin B (Fungisome TM) versus conventional amphotericin B in the empirical treatment of febrile neutropenia in India

Indian Journal of Cancer

Volumn 49, Issue 1, 2012, Pages 107-113

  Jadhav, M P ^a   Shinde, V M ^a   Chandrakala, S ^a   Jijina, F ^a   Menon, H ^b   Arora, B ^b   Kurkure, P A ^b   Parikh, P M ^b   Kshirsagar, N A ^a  

^a KEM HOSPITAL   (India)

^b TATA MEMORIAL HOSPITAL   (India)

Author keywords

Febrile neutropenia; leukemia; liposomal amphotericin B

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX;

ADOLESCENT; ADULT; CHILL; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; FEVER; HEADACHE; HUMAN; INDIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; RANDOMIZED CONTROLLED TRIAL; RIGOR; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VOMITING;

ADOLESCENT; ADULT; AMPHOTERICIN B; ANTIFUNGAL AGENTS; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INDIA; MALE; MIDDLE AGED; MYCOSES; NEUTROPENIA; SAFETY; TREATMENT OUTCOME;

EID: 84865250830     PISSN: 0019509X     EISSN: 19984774     Source Type: Journal    
DOI: 10.4103/0019-509X.98933     Document Type: Conference Paper

References (15)

1. Vartivarian SE, Anaissie EJ, Bodey GP. Emerging fungal pathogens in immunocrompromised patients: Classification, diagnosis, and management. Clin Infect Dis 1993;17:S487-91. (Pubitemid 23322843)
2. Jehu V. Managing fungal and viral infection in the immunocomprised host. Rev Res Cancer Res 1998;108:61-70.
3. Goodrich JM, Reed EC, Mori LD. Clinical features and analysis of risk factors for invasive candidal infection after marrow transplantation. J Infect Dis 1991;164:734-40.
4. Guiot HF, Fibber WE, Van T, Wout JK. Risk factors for fungal infections in patients with malignant haematological disorders: Implications for empirical therapy and prophylaxis. Clin Infect Dis 1994;18:525-32. (Pubitemid 24106902)
5. Morrison SB, Longworth DL, Goormastic M. Early infectious complications in autologous bone marrow transplantation: A review of 219 patients. Bone Marrow Transplant 1996;18:265-71. (Pubitemid 26283673)
6. Gotzsethe PC, Johansen HK. Metaanalysis of prophylactic or empirical antifungal treatment or placebo or no treatment in patients with cancer complicated by neutropenia. Br Med J 1997;314:1238-44. (Pubitemid 27173908)
7. Bodhe PV, Kotwani RN, Kirodian BG, Kshirsagar NA, Pandya SK. Open Label, Randomised, Comparative Phase III Safety and Efficacy Study with Conventional Amphotericin B and Liposomal Amphotericin B in patients with systemic Fungal Infection. J Assoc Physicians India 2002;50:662-70.
8. Denning DW, Stevens DA. Antifungal and surgical treatment of Invasive aspergillosis: Review of 2121 published cases. Review of Inf Dis 1990;12:1147-201.
9. Gokhale PC, Kotwani RN, Dange SY, Kshirsagar NA, Pandya SK. Preclinical and Pharmaceutical testing of liposomal amphotericin B. Ind J Med Res 1993;98:75-8. (Pubitemid 23251629)
10. Ahmad I, Sarkar AK, Bachhawat BK. Effect of cholesterol in various liposomal compositions on the in vivo toxicity, therapeutic efficacy and tissue distribution of amphotericin B. Biotechnol Appl Biochem 1990;12:550-6. (Pubitemid 20355160)
11. Walsh TJ, Finberg RW, Andt C, Hiemenz J, Schwartz C, Bodensteiner D. Liposomal amphotericin B for empirical therapy in patients with persistant fever and neutropenia. N Engl J Med 1999;340;764-71. (Pubitemid 29114295)
12. Maertens JA, Madero LR, Anne F, Lehrnbecher T, Groll AH, Jafri HS. et al. A randomized, double-blind, multicenter study of caspofungin versus liposomal Amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia. Pediatr Infect Dis J 2010;29:415-20.
13. Wingard JR, White M, Anaissie E, Raffali J. Goodmann J, Arrieta A. A randomized, double blind comparative trial evaluating the safety of amphotericin B versus liposomal amphotericin B complex in the empirical treatment of neutropenia. Clin Infect Dis 2001;31:1156-63.
14. Niviox Y, Velten V, Letscher B, Moghanddam S, Natarajan AC, Fohrer B, et al. Factors associated with overall and attributable mortality in invasive aspergilisis. Clin Infect Dis 2008;47:1176-84.
15. Kshirsagar NA, Panday SK, Kirodian BG, Sanath S. Liposomal drug delivery system from laboratory to clinic. J Postgrad Med 2005;51:S5-15.